da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04403022 |
Recruitment Status :
Recruiting
First Posted : May 27, 2020
Last Update Posted : May 31, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer Benign or Malignant Rectal or Colon Tumors | Device: Robotic Assisted Surgery | Not Applicable |
Primary Performance:
-
The primary performance endpoint will be assessed as the ability to complete the planned da Vinci SP-assisted colorectal procedure without conversion to an alternate approach. Conversion* to an alternate approach comprises conversion to open, multiport laparoscopic**, multiport robotic or hand-assisted§ approach requiring undocking of the da Vinci SP Surgical System in order to complete the planned procedure using the alternate approach.
- Performing an extracorporeal anastomosis is not considered a conversion ** Use of additional assistant laparoscopic port(s) is not considered a conversion § Laparoscopic or robotic with hand assistance
Primary Safety:
• The primary safety endpoint will be assessed as the incidence of all intraoperative and post-operative adverse events that occur through the 42-day follow-up period
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | A Prospective, Multi-Center Investigation of the da Vinci SP® Surgical System in Colorectal Procedures for Benign and Malignant Disease |
Actual Study Start Date : | June 3, 2021 |
Estimated Primary Completion Date : | June 30, 2023 |
Estimated Study Completion Date : | October 2028 |
Arm | Intervention/treatment |
---|---|
Single arm
Colorectal procedure will be performed by da Vinci SP® Surgical System
|
Device: Robotic Assisted Surgery
da Vinci SP Surgical System, instruments, and accessories in complex colorectal procedures such as low anterior resection procedure or right colectomy with or without total mesorectal excision |
- Performance [ Time Frame: IntraOperative period ]Performance defined as ability to complete the planned da Vinci SP-assisted colorectal procedure without conversion to an alternate approach.
- Adverse Events Rates [ Time Frame: Intraoperative through the 42-day postoperative period ]Safety defined as the incidence of all intraoperative and post-operative adverse events that occur through the 42-day follow-up period

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years
- BMI ≤ 35
- Candidate for single-port robotic-assisted surgery for low anterior resection with or without total mesorectal excision or right colectomy procedures
- ASA ≤ 3
- Willing and able to provide a written informed consent document
- Willing and able to comply with the study protocol requirements including perioperative follow-up examinations at 14 days, 42 days post operatively, and post-market long-term follow-up on an annual basis through 5 years
Exclusion Criteria:
- Clinical or radiological evidence of metastatic disease
- Life expectancy less than 6 months
- Cancer of the anal canal requiring an abdominoperineal resection
- Subjects with threatened mesorectal margins (≤1 mm) on MRI or ultrasound (for LAR ONLY)
- Subjects with planned major concomitant procedures (eg. hepatectomaies, other intestinal resections) or emergent case
- Subjects undergoing both LAR/TME and right colectomy during the same operation
- Preoperative colonoscopy demonstrating synchronous colorectal cancer
- History of inflammatory bowel disease
- Subject has a known bleeding or clotting disorder
- Uncontrolled illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Subject is contraindicated for general anesthesia or surgery
- Subject had prior incisional hernia with mesh repair
- Subject belongs to vulnerable population
- Subject is pregnant or suspected to be pregnant
Intraoperative Exclusion Criteria:
• Subject presents with adhesions or scarring in the pelvis which in the opinion of the investigator limits the ability to perform the minimally invasive procedure

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04403022
Contact: Alex Valencia, MS | 408-523-8181 ext #6109317 | alex.valencia2@intusurg.com | |
Contact: Janet Shelly | Janet.Shelley@intusurg.com |
United States, Florida | |
Mayo Clinic - Jacksonville | Recruiting |
Jacksonville, Florida, United States, 32224 | |
Contact: Amit Merchea, MD 904-953-2000 | |
Principal Investigator: Amit Merchea, MD | |
Adventist Health System/Sunbelt | Completed |
Orlando, Florida, United States, 32803 | |
United States, Minnesota | |
Mayo Clinic | Active, not recruiting |
Rochester, Minnesota, United States, 55905 | |
United States, Nevada | |
MountianView Hospital | Recruiting |
Las Vegas, Nevada, United States, 89128 | |
Contact: Garrett Friedman, MD 702-962-2300 | |
Principal Investigator: Garrett Friedman, MD | |
United States, Pennsylvania | |
Allegheny General Hospital | Recruiting |
Pittsburgh, Pennsylvania, United States, 15212 | |
Contact: James McCormick, DO 412-359-3901 | |
Principal Investigator: James McCormick, DO | |
United States, Texas | |
Houston Methodist Research Institute | Active, not recruiting |
Houston, Texas, United States, 77030 | |
United States, Washington | |
MultiCare - Tacoma | Recruiting |
Tacoma, Washington, United States, 98405 | |
Contact: Laila Rashidi, MD 253-301-5050 | |
Principal Investigator: Laila Rashidi, MD | |
Korea, Republic of | |
Ulsan University Hospital | Recruiting |
Ulsan, Dong-gu, Korea, Republic of, 25 Daehakbyeongwon-ro | |
Contact: Song soo Yang, MD | |
Ewha Womans University College of Medicine | Recruiting |
Seoul, Gangseo-gu, Korea, Republic of, Gonghang-daero | |
Contact: Gyoung Tae Noh, MD |
Study Director: | Kathryn Wine | Medical Affairs Director |
Responsible Party: | Intuitive Surgical |
ClinicalTrials.gov Identifier: | NCT04403022 |
Other Study ID Numbers: |
dV SP - CR-01 |
First Posted: | May 27, 2020 Key Record Dates |
Last Update Posted: | May 31, 2023 |
Last Verified: | May 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |